Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
HOOK HOOKIPA Pharma Inc
- Stocks
- Healthcare
- NASDAQ: HOOK
Price (delayed)
$1.3
Market cap
$15.68M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.47
Enterprise value
-$23.23M
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body's immune system.
Highlights
The debt has dropped by 87% year-on-year and by 69% since the previous quarter
The EPS has soared by 60% YoY and by 7% from the previous quarter
HOOKIPA Pharma's gross profit has surged by 118% YoY but it has decreased by 12% QoQ
The revenue has soared by 118% YoY but it has decreased by 12% QoQ
The company's equity fell by 43% YoY and by 29% QoQ
HOOK's quick ratio is down by 21% YoY and by 13% from the previous quarter
Key stats
What are the main financial stats of HOOK
Market
Valuations
Earnings
Shares outstanding
12.06M
Market cap
$15.68M
Enterprise value
-$23.23M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.31
Price to sales (P/S)
0.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.53
Revenue
$43.95M
Gross profit
$43.95M
Operating income
-$51.46M
Net income
-$43.5M
EBIT
-$43.61M
EBITDA
-$40.85M
Free cash flow
-$77.17M
Per share
Balance sheet
Liquidity
EPS
-$3.47
EPS diluted
-$3.47
Free cash flow per share
-$6.4
Book value per share
$4.25
Revenue per share
$3.65
TBVPS
$6.85
Total assets
$82.55M
Total liabilities
$31.33M
Debt
$875,000
Equity
$51.21M
Working capital
$56.01M
Debt to equity
0.02
Current ratio
3.27
Quick ratio
2.57
Net debt/EBITDA
0.95
Margins
Efficiency
Dividend
EBITDA margin
-93%
Gross margin
100%
Net margin
-99%
Operating margin
-117.1%
Return on assets
-37.6%
Return on equity
-55.5%
Return on invested capital
-178.2%
Return on capital employed
-75.3%
Return on sales
-99.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HOOK stock price
How has the HOOKIPA Pharma stock price performed over time
Intraday
-11.56%
1 week
-2.99%
1 month
65.39%
1 year
-83.75%
YTD
-35.32%
QTD
20.37%
Financial performance
How have HOOKIPA Pharma's revenue and profit performed over time
Revenue
$43.95M
Gross profit
$43.95M
Operating income
-$51.46M
Net income
-$43.5M
Gross margin
100%
Net margin
-99%
HOOKIPA Pharma's gross profit has surged by 118% YoY but it has decreased by 12% QoQ
The revenue has soared by 118% YoY but it has decreased by 12% QoQ
The net margin has surged by 76% year-on-year but it has declined by 14% since the previous quarter
The operating margin has surged by 76% year-on-year and by 3.9% since the previous quarter
Price vs fundamentals
How does HOOK's price correlate with its fundamentals
Growth
What is HOOKIPA Pharma's growth rate over time
Valuation
What is HOOKIPA Pharma stock price valuation
P/E
N/A
P/B
0.31
P/S
0.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.53
The EPS has soared by 60% YoY and by 7% from the previous quarter
The P/B is 74% below the 5-year quarterly average of 1.2 and 48% below the last 4 quarters average of 0.6
The company's equity fell by 43% YoY and by 29% QoQ
The revenue has soared by 118% YoY but it has decreased by 12% QoQ
The price to sales (P/S) is 95% lower than the 5-year quarterly average of 7.0 and 64% lower than the last 4 quarters average of 1.0
Efficiency
How efficient is HOOKIPA Pharma business performance
The ROS has soared by 75% YoY but it has contracted by 15% from the previous quarter
The company's return on invested capital has surged by 69% YoY and by 9% QoQ
HOOKIPA Pharma's return on equity has increased by 35% YoY but it has decreased by 13% QoQ
The ROA is up by 22% YoY but it is down by 18% from the previous quarter
Dividends
What is HOOK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HOOK.
Financial health
How did HOOKIPA Pharma financials performed over time
The total assets is 163% more than the total liabilities
The total liabilities has dropped by 56% year-on-year and by 17% since the previous quarter
The total assets has contracted by 49% YoY and by 25% from the previous quarter
The debt is 98% smaller than the equity
The debt has dropped by 87% year-on-year and by 69% since the previous quarter
HOOKIPA Pharma's debt to equity has shrunk by 71% YoY and by 50% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.